ForsLean® Safety Confirmed in Scientific Review

ForsLean® Safety Confirmed in Scientific Review

PISCATAWAY, N.J.Sabinsa Corp.(www.sabinsa.com) released results of an independent review of the safety ofForsLean®, its patented Coleus forskohlii extract,that show the ingredient is safe for use in dietary supplements. CANTOX HealthSciences International reviewed data from third-party literature and Sabinsasscientific research, and issued a letter stating, the available informationsupports the safety of ForsLean at the intake level of 500 mg/d, resulting in adose of 50 mg of forskolin.

Muhammed Majeed, founder and chief executive officer ofSabinsa, noted the review confirms the safety of the ForsLean brand, rather thanjust generic Coleus. Our ForsLean composition is one of the very few weightmanagement ingredients currently available on the market that has gone throughthis type of rigorous independent, third party safety review, added ToddNorton, Sabinsas president. At a time when weight management products areunder intense scrutiny, this should lay to rest any concerns regarding thesafety of ForsLean for oral dosage use in dietary supplements at its clinicallyevaluated level.